News and Trends 5 Jul 2022 Novartis Pharmaceuticals UK launches health-tech investor partnership for cardiovascular care Novartis Pharmaceuticals UK has launched the Novartis Biome UK Heart Health Catalyst 2022, in a world-first investor partnership with Medtronic ltd, RYSE Asset Management, and Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+. The initiative aims to identify and implement solutions that empower patients to improve their heart health, and to […] July 5, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 11 Oct 2021 A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology CAR-T therapy has been hailed as a cure for cancer, but what really is this ‘miraculous technology’ and what can we actually expect from it? The field of immuno-oncology is booming with billions of euros in investment. The ability to rewire our own immune system to fight cancer has certainly created huge expectations. After the […] October 11, 2021 - 10 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jul 2021 British Diagnostics Biotech Becomes Social Enterprise After Acquisition UK rapid diagnostics company Mologic will convert into a social enterprise after being acquired by a group of philanthropic funds and investors, in what experts predict may become an increasingly popular trend. The British biotech Mologic will entirely reinvest any profits into widening global access to affordable medical technology after being acquired in a deal […] July 30, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 27 Apr 2021 EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations centered mostly on improving existing approaches. Which areas of multiple sclerosis treatment need more options? At the end of March, the EMA made key decisions on three treatments for multiple sclerosis (MS), a chronic neurodegenerative disease affecting 2.5 million people […] April 27, 2021 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2020 Update: Novartis’ Gene Therapy Zolgensma Gets Nod from EU Update (19/05/2020): The gene therapy Zolgensma, developed by the big pharma Novartis and approved in the US last year, has received conditional approval in Europe for the treatment of spinal muscular atrophy (SMA). The gene therapy is approved to treat patients with a clinical diagnosis of SMA type 1 or SMA patients that have up […] May 19, 2020 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Apr 2020 Update: FDA Imposes No Penalties for Novartis Data Manipulation Scandal Update (02/04/2020): The FDA has concluded an investigation into a data manipulation scandal surrounding the approval of Novartis’ gene therapy Zolgensma, and has decided against sanctions. The FDA launched an investigation into the manipulated data surrounding the gene therapy application last year, and recently reported that the investigated data violations didn’t meet the threshold for […] April 2, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 25 Nov 2019 Novartis Enters RNA Therapeutics with Medicines Company Merger Novartis is to acquire The Medicines Company and its late-stage RNA interference drug designed to protect against cardiovascular disease in twice-yearly shots. Novartis will pay €8.8B ($9.7B) to acquire The Medicines Company, which is based in the US and focuses on developing the RNA drug inclisiran for the treatment of cardiovascular disease and renal impairment. […] November 25, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2019 European Project Launches to Tailor Autoimmune Disease Treatments Public and private organizations across Europe will pool their resources in an €80M project to discover biomarkers that can predict which patients will respond best to treatments for autoimmune diseases. The project is called Taxonomy, Treatments, Targets and Remission, or 3TR for short, and is funded by the EU’s Innovative Medicines Initiative for the next […] October 31, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 30 Oct 2019 Trial Testing Spinal Application of Zolgensma Put on Hold by FDA The FDA has placed a partial hold on clinical trials testing a new application method for Zolgensma, Novartis’ gene therapy for the genetic disease spinal muscular atrophy, after it showed the potential to cause serious side effects in animal models. Spinal muscular atrophy is a life-threatening condition that usually arises when the patient is between […] October 30, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 29 Oct 2019 MorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II Development of MorphoSys, Galapagos, and Novartis’ first-in-class antibody drug has been discontinued during a phase II trial after an interim analysis suggested it wouldn’t meet its main endpoint of reducing eczema symptoms. The drug was being developed to treat the inflammatory skin condition atopic dermatitis, also known as eczema. It arose from a collaboration between […] October 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2019 Top Cardiology Biotech News from the ESC Conference 2019 Many cardiology companies and academics gathered in Paris earlier this week to showcase their latest research into cardiovascular diseases. Read on for a roundup of the most exciting cardiology news from the biotech scene. The European Society of Cardiology teamed up with the World Heart Federation this year to arrange a conference themed on global […] September 5, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Mar 2019 Seventure Continues Microbiome Investment Success with Second Fund After the success of the world’s first fund dedicated to companies in nutrition, digital health, and the microbiome, the French venture capital firm Seventure Partners has completed the first closing of a second microbiome fund, which is expected to total €200M. The fund is the successor to Seventure’s Health for Life Capital fund, which was […] March 5, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email